Although ibrutinib (Bruton’s Tyrosine Kinase (BTK) inhibitor) shows promise in chronic myeloid and lymphocytic leukemia patients, this therapeutic approach fails to achieve complete, sustained responses in DLBCL patients because of inherent resistances due to the additional genetic lesions in other components of the BCR pathway and acquired mutations in BTK [8,13,14]. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.